Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea (WinMal)
WinMal Trial: Spatial Emanator Deployment Strategies for Malaria Control in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors. Spatial emanators are new devices that release insecticide into the air to repel or kill mosquitoes. This study will test whether these devices reduce malaria infections in rural villages in Madang Province by comparing households using indoor or outdoor devices with those without them. The results will help guide national malaria control strategies.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The WinMal trial is a large-scale cluster randomised control trial investigating whether spatial emanators reduce transmission of malaria infections. The study is being conducted with 150 rural villages in Bogia, Sumkar, Madang and Rai Coast districts of Madang Province, Papua New Guinea.
The trial will address the question: 'Do Guardian spatial emanators reduce malaria transmission when deployed in protected outdoor spaces or inside houses in PNG?'
The trial will evaluate the effectiveness, acceptability and feasibility of Guardian SE deployed indoors and outdoors for malaria prevention in PNG.
The WinMal trial will provide evidence to guide PNG National Department of Health decisions on how spatial emanators could be deployed alongside ITNs to address gaps in protection from outdoor biting.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Paul Daly, MPH MID
- Telefonnummer: +61 3 9282 2111
- E-post: paul.daly@burnet.edu.au
Studiesteder
-
-
Madang Province
-
Madang, Madang Province, Papua Ny-Guinea
- Sumkar, Bogia, Rai Coast and Madang Districts of Madang Province, Papua New Guinea
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Children aged 9-14 years at enrolment
- Sleeps in a household within allocated cluster >90% of the nights during any given month
Exclusion Criteria:
- Dissent (by child) to participate in the study
- No parental consent provided through the signing of informed consent form
- Unwillingness to take G6PD-guided radical cure treatment at enrolment with no previous ADRs to AL or PQ
- Plans for extended travel (>2 weeks) outside of household/cluster during the study
- G6PD activity ≤6.0 U/g Hb at screening
- Measured baseline of ≤8 mg/dL or who have signs of clinical decompensation
- Participating or planning to participate in another clinical trial investigating a drug, vaccine, medical device, or procedure during the study period
- Currently taking malaria prophylaxis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Outdoor intervention arm
Guardian spatial emanators deployed in protected outdoor spaces, households will continue to use ITNs as per routine National Malaria Control Program |
Guardian spatial emanators deployed in protected outdoor spaces |
|
Eksperimentell: Indoor intervention arm
Guardian spatial emanators deployed inside houses, households will continue to use ITNs as per routine National Malaria Control Program |
Guardian spatial emanators deployed inside houses |
|
Ingen inngripen: Control arm
No spatial emanators deployed, households will continue to use ITNs as per routine National Malaria Control Program |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Effectiveness of Guardian Spatial Emanator
Tidsramme: 12 months
|
Time to first Plasmodium spp. infection detected by PCR at monthly follow-up visits or symptomatic ad-hoc visit between follow-ups over the 12-month intervention period in cohort participants from the core of the clusters. |
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Effectiveness of Guardian Spatial Emanator
Tidsramme: 12 months
|
Time to first PCR-confirmed P. falciparum infection over the 12 months of follow-up. Time to first PCR-confirmed P. vivax infection over the 12 months of follow-up. |
12 months
|
|
Effectiveness of Guardian Spatial Emanator
Tidsramme: 6 months
|
Time to first PCR-confirmed Plasmodium spp infection over the first 6 months of follow-up. Time to first PCR-confirmed P. falciparum infection over the first 6 months of follow-up. Time to first PCR-confirmed P. vivax infection over the first 6 months of follow-up. |
6 months
|
|
Effectiveness of Guardian Spatial Emanator
Tidsramme: 12 months
|
Incidence of PCR-confirmed Plasmodium spp infections (first-time & recurrent together) in first 6m & full 12m. Incidence of PCR-confirmed Pf infections (first-time & recurrent together) in first 6m & full 12m. Incidence of PCR-confirmed Pv infections (first-time & recurrent together) in first 6m & full 12m Incidence of clinical episodes of malaria (first-time & recurrent together) in first 6m & full 12m Incidence of Pf clinical episodes of malaria (first-time & recurrent together) in first 6m & full 12m Incidence of Pv clinical episodes of malaria (first-time & recurrent together) in first 6m & full 12m Incidence of new Pf blood stage infections (molecular force of blood-stage infection - Pf molFOB) in first 6m & full 12m Incidence of new Pv blood stage infections (molecular force of blood-stage infection - Pv molFOB) in first 6m & full 12m Incidence of new blood stage infections (molecular force of blood-stage infection for Pf and Pv molFOB combined) in first 6m & full 12m |
12 months
|
|
Difference between indoor and outdoor arms
Tidsramme: 12 months
|
Time to first Plasmodium spp. infection detected by PCR at monthly follow-up or symptomatic ad-hoc visit between follow-ups visits over the 12-month intervention period in cohort participants from the core of the clusters. |
12 months
|
|
Sensitivity of the estimates for epidemiological outcomes
Tidsramme: 12 months
|
Spillover-adjusted estimates of intervention effectiveness for epidemiological endpoints, incorporating data from cluster buffer zone participants. |
12 months
|
|
Anopheles species composition
Tidsramme: 12 months
|
Anopheles species composition in a subset of clusters, in the pre-deployment baseline period and at the end of the intervention. |
12 months
|
|
Presence of insecticide resistance mutations
Tidsramme: 12 months
|
Prevalence of insecticide resistance markers in a subset of clusters in the pre-deployment baseline period and at the end of the intervention. |
12 months
|
|
Acceptability of spatial emanators
Tidsramme: 12 months
|
Qualitative outcomes from Photovoice methodology, and associated focus group discussions with community members, followed by thematic analysis of drivers of behaviour change, barriers and enablers of spatial emanator acceptance and consistent use. |
12 months
|
|
Feasibility of spatial emanators
Tidsramme: 12 months
|
Qualitative outcomes from key informant interviews with key study staff and health system stakeholders at district, provincial, and national level followed by descriptive summary of barriers and enablers to distribution, implementation & scale-up. |
12 months
|
|
Cost effectiveness of Guardian spatial emanators
Tidsramme: 12 months
|
The costs of deploying spatial emanators (either indoor or outdoor) and the incremental cost-effectiveness ratios when compared with current practice. |
12 months
|
|
Self-reported adverse events
Tidsramme: 12 months
|
Incidence of self-reported adverse events (AEs) and/or serious adverse events (SAEs) assessed as possibly or likely related to Guardian spatial emanators among cohort participants (through monthly follow-up) and wider community through passive surveillance. |
12 months
|
|
Coverage, attrition and re-location of spatial emanators
Tidsramme: 12 months
|
Proportion of households with emanators in place at scheduled monitoring visits, the attrition rate per cluster per scheduled monitoring visit period, timing of redistribution events recorded per cluster. |
12 months
|
|
Transfluthrin quantity, installation environment and bioefficacy
Tidsramme: 12 months
|
Mass percent transfluthrin retained in the spatial emanators related to installation environment and bioefficacy measure/s (e.g., knock down and mortality of colony mosquitoes exposed to spatial emanators). |
12 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Leanne Robinson, MPH PhD, Burnet Institute
- Hovedetterforsker: Moses Laman, MBBS PHD, Papua New Guinea Institute of Medical Research
- Hovedetterforsker: Stephan Karl, PhD, James Cook University, Queensland, Australia
- Hovedetterforsker: Jacob Kisomb, MBBS, National Department of Health, Papua New Guinea
- Hovedetterforsker: Maria Ome-Kaius, MBBS PhD, Papua New Guinea Institute of Medical Research
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NATNAT WinMal cRCT
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .